Graseby Syringe Driver Update
| From 2007CPCRE has worked with Palliative Care Queensland and Palliative Care Australia (PCA) to develop a nationally coordinated response to the 2007 withdrawal of the Graseby Syringe Driver from sale in Australia. Smiths Medical Australasia (SMA) announced on 24th August 2007 that: "Supply of the MS16a and MS26 will continue until close of business on 3rd October... SMA will continue to service and support for these devices will continue for a minimum of 5 years". Together with PCA, CPCRE has monitored the situation and sought information about alternative devices. There have been no impediments to continued use of syringe drivers already in the community. For Palliative Care Australia's Graseby information, originally released December 2007, see the Palliative Care Australia 'Report on subcutaneous infusion devices' at www.palliativecare.org.au/Syringedrivers.aspx When considering an alternative device, factors such as safety, cost, weight, portability, and cost of consumables should be considered.
|
Background
The Graseby Syringe Driver has been in common use for many years where subcutaneous infusion of medications for palliative patients, particularly in the community, is required. Its popularity relates to its ease of use for practitioners, portability, and relatively low cost in comparison with other available infusion devices. In addition, the consumables for the GSD, such as extension tubing and syringes, are standard and low cost.
Given the central role that the GSD has played in palliative symptom management, the Centre for Palliative Care Research and Education initiated a process to seek information about alternative subcutaneous infusion device options.
A working party facilitated by CPCRE was drawn from a wide cross section of people with clinical and technical backgrounds in Queensland Health, as well as from the community sector.